Accordingly, clinical studies using ketoprofen, a nonsteroidal anti-inflammatory drug that can inhibit 5-LOX more than COX (inhibit 5-LOX together with COX) have demonstrated that treatments could minimize subjective lymphedema-related symptoms but failed to reduce the lymphedema volume and improve swelling [2]. This evidence concerns the gene ALOX5 and lymphedema.